Burden of adult-onset Still's disease: A systematic review of health-related quality of life, utilities, costs and resource use.

Autor: Ruscitti P; Department of Applied Clinical Sciences and Biotechnology, Rheumatology Unit, University of L'Aquila, L'Aquila, Italy., Feist E; Helios Specialist Clinic Vogelsang-Gommern, Department of Rheumatology, Helios Fachklinik, Sophie-von-Boetticher-Straße 1, 39245, Vogelsang-Gommern, Germany., Canon-Garcia V; Novartis AG, Fabrikstrasse 2, CH-4056 Basel, Switzerland., Rabijns H; Novartis NV/SA, Medialaan 40, B-1800 Vilvoorde, Belgium., Toennessen K; Novartis GmbH, Roonstr. 25, D-90429 Nuernberg, Germany., Bartlett C; York Health Economics Consortium (YHEC), Enterprise House, Innovation Way University of, York YO10 5NQ, England. Electronic address: Chris.bartlett@york.ac.uk., Gregg E; York Health Economics Consortium (YHEC), Enterprise House, Innovation Way University of, York YO10 5NQ, England., Miller P; York Health Economics Consortium (YHEC), Enterprise House, Innovation Way University of, York YO10 5NQ, England., McGonagle D; University of Leeds School of Medicine, Leeds, LS2 9JT, England.
Jazyk: angličtina
Zdroj: Seminars in arthritis and rheumatism [Semin Arthritis Rheum] 2023 Dec; Vol. 63, pp. 152264. Date of Electronic Publication: 2023 Sep 26.
DOI: 10.1016/j.semarthrit.2023.152264
Abstrakt: Adult-onset Still's disease (AOSD) poses a not well estimated burden on patients and healthcare systems. To assess this burden, a systematic review (SR) was undertaken to identify health-related quality of life (HRQoL), utilities, costs and healthcare resource use data. Searches of twelve databases, four conferences, and three key technology assessment and regulatory agency websites were conducted in August 2022. Reference lists of retrieved SRs published since 2017 were also checked. Overall, 16 studies were eligible for inclusion. Eight studies reported HRQoL outcomes, one of which also reported utilities data. Two studies reported direct costs outcomes, and seven reported healthcare resource use data. No indirect costs were identified. A range of outcomes were reported, thus limiting the comparability of results across studies. SF-36 data were impaired in AOSD on most scales, especially those concerning physical activity. Mean SF-36 data were lower across all subscales in patients with active AOSD compared with inactive AOSD. Biologic therapy showed improvements in the SF-36 physical health summary. Utility scores (one study) were significantly lower for AOSD than for healthy controls. Limited direct economic costs data were identified but were substantial where reported. Hospital length of stay ranged from 6.1 to 23.5 days. The SR showed there is a paucity of research reporting the HRQoL and cost burden of AOSD.
Competing Interests: Declaration of Competing Interest PR, EF and DMcG did not receive any remuneration from Novartis related to this project. EF received honoraria for consultancy and lectures from Abbvie, Lilly, Galapagos, Pfizer, Roche/Chugai, Sobi, Novartis, Sanofi. DMcG received honoraria or grant funding Abbvie, Lilly, Pfizer, Sobi, Novartis, Sanofi. PR received speaker honoraria from Abbvie, BMS, Janssen, Novartis, Sobi outside this work.
(Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: